Introduction
============

Ovarian cancer is a highly aggressive gynecological cancer and the fifth common cause of death in woman worldwide [@B1]. Due to the development of some treatments and regimens in recent decades, some significant treatment achievements have been made for ovarian cancer patients, however, the 5-year survival rate for the ovarian cancer patients is still only 30% [@B2]. These high mortality can be mainly explained the fact that 75% of the ovarian cancer patients are at an advanced stage. And the representative characteristics of the advanced ovarian cancer are its rapid growth and wide metastatic diseases within the peritoneal cavity [@B3]. Therefore, unraveling the factors in the process of the ovarian cancer progression is important for providing novel biomarkers for prognosis and future therapeutic interventions.

The tripartite motif-containing (TRIM) proteins consist of three common N-terminal domains: a really interesting new gene (RING) domain, one or two b-boxes and a coiled-coil domain [@B4]. The TRIM superfamily includes more than 70 known protein members in human, and increasingly emerging evidences have suggested that some TRIM proteins are involved in cancer and offer some diagnostic biomarkers and new potential therapeutic targets [@B5]-[@B7]. Moreover, studies have showed that TRIM proteins can regulate cancer cell proliferation, migration, apoptosis, adhesion, invasion and metastasis [@B8]-[@B10]. TRIM59, as a cytoplasmic protein, has a specifically increased expression in breast, lung, parotid, gastrointestinal, female genital tract, bladder, head prostate, and neck mucosal tumor area [@B11]. Recently, our data has showed that both the mRNA and protein levels of TRIM59 are up-regulated in gastric cancer tissues compared with normal gastric tissues and associated with the poor prognosis of gastric cancer patients. Moreover, we also validate that TRIM59, a putative ubiquitin ligase, can interact with p53 promoting its ubiquitination and degradation, and then to induce gastric cancer cell growth and inhibit apoptosis [@B12], [@B13]. However, the exact roles of TRIM59 in ovarian cancer are still unknown.

In this study, we investigated the expression of TRIM59 in ovarian cancer and its association with the clinical parameters. We further explored the roles of TRIM59 in ovarian cancer cell proliferation, migration and clone formation *in vitro* and the growth *in vivo*. Simultaneously, we also investigate how TRIM59 regulate these cellular functions.

Materials and Methods
=====================

Patients and samples
--------------------

This study was granted by Institutional Review Board of Shanghai Jiao Tong University School of Medicine prior to this study. All subjects provided their written informed consent and were assured of their anonymity and the confidentiality of the data obtained. Three normal ovarian epithelial tissues, four paired fresh ovarian epithelial carcinomas and the matched metastatic ovarian cancer tissues were obtained in surgery by pathology professionals. In addition, we purchased a commercial ovarian cancer tissue microarray (TMA) consisting of 192 ovarian adenocarcinomas, 10 para-carcinomas and 6 normal ovarian tissues (product lot number: OV20810, Xi\'an Alenabio Co, Xi\'an, China) and their detailed clinicopathological information.

Western blotting
----------------

The Western blotting was carried out as described as before [@B13], and the anti-TRIM59 (Abcam), anti-FLAG (Cell Signaling Technology), anti-Myc (Cell Signaling Technology), and anti- Annexin A2 (Cell Signaling Technology) were used as the primary antibodies. The anti-GAPDH (Epitomics) was used for the protein loading control. Each blotting was repeated three times.

Cell lines, plasmids, transfection and lentivirus production
------------------------------------------------------------

Ovarian cancer cell lines, ES2, HO8910-PM, HO8910, SKOV3, A2780, OV2008, and OVCAR3 were cultured in DMEM medium (Invitrogen) supplemented with 10% fetal bovine serum, 10 u/mL penicillin G/streptomycin, 2 mM L-glutamine. Cells were maintained at 37°C in a humidified atmosphere containing 5% CO~2~.

Lentiviral plasmids containing two shRNA sequencesfor TRIM59 and the scramble shRNA fragments were generated in our previous study [@B13]. The full-length cDNAs for TRIM59 were amplified by PCR and ligated into a PLV.Ex2d.P/puro-EF1A vector that contains three copies of FLAG. All clones were confirmed by DNA sequencing.

The lentiviral plasmids and the packaging vectors pCMV-DR8 and pMD2.2 were transiently co-transfected into 293T cells using the calcium phosphate transfection method. After 48 hours of co-transfection, lentiviral supernatant was harvested to infect cell lines. These infected cells were stably selected with puromycin at a final concentration of 8 mg/ml for 2 weeks.

Immunoflurescence
-----------------

The immunofluorescence was performed the same as the previous reports [@B13], [@B14]. The frozen human ovarian cancer and the normal ovarian tissues were sectioned with a thickness of 10 μm. Primary antibody against TRIM59 (Abcam) were used overnight at 4°C. The cell nucleus was counterstained with 5 μg/ml DAPI (Beyotime). The intracellular distributions of the target proteins were analyzed and photographed using confocal fluorescent microscopy with excitation at 488 nm (for FITC) and 340 nm (for DAPI).

Immunohistochemistry
--------------------

The standard protocol used for the immunohistochemistry was provided in our previous study [@B13]. The rabbit polyclonal anti-TRIM59 (diluted at 1:100, Abcam) was incubated as the primary antibody for 1 hour at 37°C. The slide without primary antibody incubation was used as negative control. The nucleus was counterstained with Hematoxylin. The TMA immunostaining images were captured using a Leica DM2500 microscope and analyzed by Image-Pro Plus 6.0 software.

The signals were quantified according to both the intensity and percentage of cells with positive staining. The TRIM59 staining intensity was scored 0 to 3 (0 = negative; 1 = weak; 2 = moderate; 3 = strong). The percentage of TRIM59-positive stained cells was also scored into four categories: 1 (0%-25%), 2 (26%-50%), 3 (51%-75%) and 4 (76%-100%). The level of TRIM59 staining was evaluated by the immunoreactive score (IRS), which is calculated by multiplying the scores of staining intensity and the percentage of positive cells. Based on the IRS, the TRIM59 staining pattern was categorized as negative (IRS: 0), low (IRS: 1-6) and high (IRS: 8-12).

Co-immunoprecipitation
----------------------

Co-immunoprecipitation was performed according to the procedure described previously [@B13]. Briefly, cellular lysates were prepared by incubating the cells in lysis buffer. The protein concentration of the lysates was determined using the BCA protein assay kit (Pierce) according to the manufacturer\'s protocol. About 500 μg protein was incubated with 2 μg specific antibodies for 12 h at 4ºC with constant rotation, then 20 μl 50% protein A or G agarose beads were then added and the incubation was continued for an additional 2 h. Beads were then washed five times using the lysis buffer, the beads were collected by centrifugation at 500 g for 5 min at 4ºC. The precipitated proteins were eluted from the beads by resuspending the beads in 2 × SDS-PAGE loading buffer and boiling for 5 min. At last, the immunoblotting was carried out in consistent with the previous experiment.

Quantitative real-time PCR (RT-PCR)
-----------------------------------

Total RNAs were extracted from the human ovarian tissues and cell lines using TRIzol reagent (Invitrogen). Then the total RNAs were reversely transcribed to cDNAs using PrimeScript RT reagent Kit with gDNA Eraser (Takara). The cDNAs were amplified with the primers: 5\'-CCTGTGTTTGAGATAGATTTAAGAGC-3\' (forward) and 5\'-GCAACAAGGTGAGACCCAGT-3\' (reverse) for TRIM59, 5\'-AAATCCCATCACCATCTTCC-3\' (forward) and 5\'-TCACACCCATGACGAACA-3\' (reverse) for GAPDH. The RT-PCR assay was carried out as described previously [@B13]. TRIM59 mRNA expression was normalized to GAPDH mRNA.

Cell proliferation assay
------------------------

5×10^3^ cells were seeded in 96-well plate and cultured for 24, 48 and 72 hours. Then 10 microliter CCK-8 solution (Dojindo Molecular Technology Inc.) was added to each well and incubated at 37°C for 2 hours. Using the microplate reader (Bio-Tek), the absorbance was measured at 450 nm.

The soft agar colony formation assay
------------------------------------

Soft-agar was pre-coated with 0.6% agarose in DMEM medium supplemented with 10% FBS in the bottom of the 6-well plates, as described previously [@B13]. 1.5×10^3^ cells suspended in 1 ml DMEM complete medium supplemented with 0.3% agar were covered into the pre-coated 6-well plates in triplicate. After 14 d, colonies were stained by 0.005% crystal violet (dissolved in methanol) for 1.5 hours, photographed and counted.

3D matrigel growth assay
------------------------

50 μl matrigel mixed with cells in 50 μl DMEM media was seeded in 24-well plates at 2.5×10^3^ cells/well in triplicate and incubated at 37°C for 30 minutes. Then 200 μl DMEM media containing 10% FBS was applied to the 24-well plate. After incubation at 37°C for another 48 hours, photos were taken under a microscope, and the microspheres formed in the matrigel were counted in five random fields.

The invasion assay
------------------

The invasion assay was carried out using Costar transwell plates with 8 μm pore size, as described previously [@B13]. The transwell plate inserts were pre-coated with matrigel and 3×10^4^ cells were seeded in serum-free medium in the upper chamber. After 24 hours incubation at 37°C, cells in the upper chamber were carefully removed with a cotton swab and the cells that had traversed the membrane were fixed in 4% formalin for 15 minutes, stained with Crystal violet (0.1% in water) for 5 minutes, and counted the permeating cells in five random fields of each insert under the inverted microscope and photographed.

*In vivo* xenograft assay
-------------------------

For the tumor xenograft assay, the nude mice were divided into three groups consisting of 10 mice each. The SKOV3 cells untreated, stably transfected by TRIM59-shRNA or vector lentviruses (1×10^6^) mixed with 100 μl matrigel were subcutaneously injected into the axillary breast fat pad of the 4-week-old female BALB/C nude mice, respectively. The tumor growth was measured by a caliper upon palpable every 5 days. Tumor volume was calculated according to the formula: V= longer dimension ×shorter dimension^2^ × 0.5. Mice were sacrificed 40 days after injection, and tumors were taken out to photo. Each of tumors was divided for maintaining in liquid nitrogen and fixation in 10% buffered formalin.

The orthotopic implantation model
---------------------------------

The SKOV3 cells with TRIM59 shRNA and scramble lentivirus were infected by the lentivirus with luciferase and green fluorescence protein (GFP), the flow cytometry was used to separate the cells with GFP. Then cells with positive GFP were injected subcutaneously with the 1×10^6^ dose into three 4-week-old female BALB/C nude mice. The nude mice were killed to harvest the tumor until the tumor volume was more than 1 cm^3^. Then, the nude mice intramuscularly anesthetized by ketamine hydrochloride (10 mg/kg). An incision was made through the right lower abdominal para rectal line and peritoneum. The right ovary was exposed, and part of the serosal membrane was scraped with forceps. The 1 mm^3^ tumor fragments were implanted into the scraped site of the serosal surface with a 5-0 absorbent suture. The ovary was then returned into the peritoneal cavity, and the abdominal wall and skin were closed with 3-0 sutures. The tumor growth was monitored every 5 days, and after 28 days of initial implantation, the mice were anaesthetized and given D-luciferin in PBS. Ten minutes after injection, bioluminescence imaging was conducted using a charge-coupled device camera (IVIS; Xenogen). Then, the mice were killed and tumors were taken out to photo. Each of tumors was divided for maintaining in liquid nitrogen and fixation in 10% buffered formalin.

Immunopurification, Coomassie Staining, and Mass Spectrometry
-------------------------------------------------------------

The 293T cells were transfected with 3×FLAG-TRIM59 for 48 hours, and the cellular lysates were prepared by incubating the cells in lysis buffer containing protease inhibitor cocktail (Roche). Anti-FLAG immunoaffinity columns were prepared using anti-FLAG M2 affinity gel (Sigma) following the manufacturer\'s suggestions. Cell lysates were applied to an equilibrated FLAG column of 1-ml bed volume to allow for adsorption of the protein complex to the column resin. After binding, the column was washed with cold PBS plus 0.1% Nonidet P-40. FLAG peptide (Sigma) was applied to the column to elute the FLAG protein complex as described by the vendor. Fractions of the bed volume were collected and electrophoresed by 4-20% SDS-PAGE. Separated protein bands were visualized by Coomassie staining.

The entire gel slice was excised into 11 pieces that were analyzed by LC-MS/MS using an LTQ-Orbitrap XL MS (Thermo Scientific, San Jose, CA) with on-line Eksigent NanoLC system (Eksigent, Dublin, CA) as described [@B15].

Statistical analysis
--------------------

All the statistical analyses were performed by SPSS 20.0 statistical software package (SPSS Inc., Chicago, IL). The Mann-Whitney U test and Kruskal-Wallis test were implemented to evaluate the relationship between TRIM59 expression and clinicopathological parameters. Data are expressed as the means ± SD. The Dunnett\'s t-test was used to assess differences within treatment groups. Differences were considered significant when *P* \< 0.05.

Results
=======

TRIM59 expression was up-regulated and positively associated with clinicopathological features in human ovarian cancer
----------------------------------------------------------------------------------------------------------------------

In order to confirm the expression of TRIM59 in human ovarian cancer, we collected 4 pairs of ovarian cancer tissues and metastatic tumors, and 3 normal ovarian epithelial tissues. RT-PCR results showed that TRIM59 mRNA expression was much higher in cancer epithelial tissues than the normal ones (Figure [1](#F1){ref-type="fig"}A). Simultaneously, using the immunofluorescence technique in the frozen sections of human ovarian cancer tissues and the normal ovarian tissues, we found that TRIM59 was mainly localized in the cytoplasm and nucleus of the ovarian cancer epithelial cells, and the TRIMP59 expression was almost negative in the normal tissues, but positive in the cancers (Figure [1](#F1){ref-type="fig"}B).

Using the immunohistochemical staining in the TMA including 192 human ovarian cancer tissues, we further explore the association between the expression of TRIM59 and the clinicopathological characters. Our data revealed that TRIM59 staining seemed to be localized in the cytoplasm and nucleus (Figure [2](#F2){ref-type="fig"}). Moreover, based on the multiplication of the staining intensity and the percentage of positive cells, the TRIM59 expression was classified as negative, low and high group. Using the appropriate statistical methods, we found that the expression of TRIM59 was positively associated with histological grades (*P* = 0.000), FIGO stages (*P* = 0.016), and metastasis (*P* = 0.027) (Table [1](#T1){ref-type="table"}). The T stage was marginally correlated with TRIM59 expression (*P* = 0.073). There was no significant association between TRIM59 expression with age, lymph node and distant metastasis.

TRIM59 expression was correlated with prognosis of ovarian cancer patients
--------------------------------------------------------------------------

To analyze the prognostic value of TRIM59 in ovarian cancer, we used an integrative data analysis tool to validate the prognostic power of biomarkers identified in the literature. The tool can be accessed online at [www.kmplot.com/ovar](http://www.kmplot.com/ovar). The tool divided the patients into two groups according to the expression of TRIM59. These groups were then compared using progression-free survival or overall survival. A Kaplan-Meier survival plot was generated and significance was computed. The data revealed that ovarian cancer patients with high TRIM59 expression were correlated with more unfavorable overall and progression-free survival than the rest patients with low TRIM59 expression (*P* = 0.0024 and *P* = 7.5×10^-6^, respectively (Figure [3](#F3){ref-type="fig"}A-B).

TRIM59 expression promoted ovarian cancer proliferation, clone formation, and invasion *in vitro*
-------------------------------------------------------------------------------------------------

To select a suitable ovarian cancer cell line, we collected 7 ovarian cell lines, ES2, HO8910-PM, HO8910, SKOV3, A2780, OV2008 and OVCAR3 to test the endogenic TRIM59 expression levels. RT-PCR results demonstrated that the SKOV3 cells had the highest endogenic TRIM59 expression in these cell lines (Figure [4](#F4){ref-type="fig"}A). Then we knocked down TRIM59 expression in SKOV3 cells using the lentivirus to study the biological function of TRIM59 in ovarian cancer. After transfection, both the mRNA level and the protein level of TRIM59 in SKOV3 cells were decreased significantly compared to the control cells (Figure [4](#F4){ref-type="fig"}B-D).

The results of CCK8 assay showed that TRIM59 knockdown significantly reduced the SKOV3 cell proliferation when compared with the paired controls (Figure [5](#F5){ref-type="fig"}A). Next, the soft agar clone formation assay was carried out to explore cell anchorage independent growth ability. Our data exhibited that the clone formation ratio of SKOV3 cells with TRIM59 knockdown had a significant decrease by about 48% after 15 days and 65% after 22 days as compared with the control ones (Figure [5](#F5){ref-type="fig"}B). The results of 3D matrigel growth assay showed that the TRIM59 knockdown in SKOV3 cells significantly reduced the number of the microspheres in comparison with the vector-infected cells (Figure [5](#F5){ref-type="fig"}C). Moreover, the transwell assay was used to assess the impact of TRIM59 on the cell invasion. Our data revealed that the invasion cell number of SKOV3 cells with knocked-down TRIM59 expression significantly decreased when compared with the control (Figure [5](#F5){ref-type="fig"}D).

TRIM59 expression accelerated ovarian cancer growth *in vivo*
-------------------------------------------------------------

To further investigate the role of TRIM59 in ovarian cancer progression, we performed the xenograft tumor assays. The SKOV3 cells untreated, stably transfected by TRIM59-shRNA or vector lentiviruses were subcutaneously injected into the axillary breast fat pad of the nude mice, respectively. And the tumor size was monitored every five days. Consistent with the findings *in vitro*, we found that the tumor size was significantly decreased after TRIM59 knockdown when compared with the control (Figure [6](#F6){ref-type="fig"}A-B).

Simultaneously, to further confirm the finding *in vivo,* we used the luciferase tagged SKOV3 cells which were stably transfected by TRIM59-shRNA or vector lentiviruses to establish the orthotopic implantation model in nude mice. The small animal living imaging method was used to evaluate and monitor ovarian cancer cell growth. Our results revealed that the orthotopic transplantation ovarian tumor growth significantly reduced in the group with TRIM59 knockdown in comparison with the corresponding control group (Figure [6](#F6){ref-type="fig"}D-E). These collective data demonstrated that TRIM59 could accelerate the cancer cells growth to promote the ovarian cancer development.

TRIM59 induced Annexin A2 expression
------------------------------------

Given the clinical and biological significance of TRIM59 in ovarian cancer, we sought to determine the biochemical mechanism of its action. In order to do so, we generated a lentiviral construct for stable expression in 293T cells (Figure [7](#F7){ref-type="fig"}A).

To identify the proteins complexes that are binding to FLAG-TRIM59, we next decided to perform mass spectrometric analysis of the protein complexes. The contracted protein pool was loaded into a single well on a gel and subjected to coomassie analysis (Figure [7](#F7){ref-type="fig"}B). The individually excised protein-containing bands, as visualized in Figure [7](#F7){ref-type="fig"}B were subjected to mass spectrometry. The results revealed that TRIM59 bound with Annexin A2, Annexin A5, Polyubiquitin-C, MDM2, Rad23b and so on (Table [2](#T2){ref-type="table"}).

It was reported that Annexin A2 was overexpressed in ovarian carcinoma tissues and promoted ovarian cancer cell proliferation and invasion [@B16], [@B17]. We over-expressed TRIM59 in an ovarian cancer cell line, A2780 cells, and performed the co-immunoprecipitation assay. Our data displayed that TRIM59 was jointed with Annexin A2 (Figure [7](#F7){ref-type="fig"}C), which was accordant with our results of the protein mass spectrometry analysis in 293T cells. Moreover, TRIM59 knockdown inhibited Annexin A2 protein expression, whereas TRIM59 over-expression up-regulated Annexin A2 expression (Figure [7](#F7){ref-type="fig"}D).

Discussion
==========

Ovarian cancer is a high life threatens in gynecological disease [@B1]. The rapid growth and extensive abdominal metastasis of ovarian cancer cells is the main causes of death in ovarian cancer patients [@B3]. Therefore, it is important to explore the exact molecular mechanisms of ovarian cancer progression in order to discover some promising prognostic biomarkers for ovarian cancer and potential novel treatment targets.

TRIM59 has been showed to play important roles in tumorigenesis and tumor progression [@B13], [@B18]. Studies have showed that TRIM59 is up-regulated in the breast, lung, parotid, gastrointestinal, female genital tract, bladder, kidney and prostate cancer, and positively associated with the poor outcome of gastric cancer patients [@B11], [@B13]. Despite this, there is no study investigating TRIM59 expression related to the progression of ovarian cancer. In this study, our data showed that TRIM59 expression was increased in ovarian cancer cell lines and tissues when compared with the normal ovarian epithelial cell line and tissues, which was consistent with the previous studies [@B11], [@B13]. Moreover, using a well-described ovarian cancer TMA with precise clinical data, we demonstrated that TRIM59 expression was positively associated with histological grades, FIGO stages, and metastasis. These findings indicated that TRIM59 expression may be related to the progression of ovarian carcinomas.

Based on our finding in the clinical data and the consensus that the speed of ovarian cancer progression depends on cancer cell growth and metastasis [@B3], we performed a series of cell line and animal experiments to investigate the possible roles of TRIM59 in ovarian cancer. In the present study, we found that TRIM59 knockdown in ovarian cancer cells inhibited the cell proliferation, anchorage independent growth, and invasion. Furthermore, TRIM59 expression in ovarian cancer cells negatively regulated the growth of the subcutaneous and orthotopic implantation *in vivo*. These data were consistent with and explained the results of the population study that TRIM59 expression was positively associated with FIGO stages and metastasis.

Annexins are widely involved in regulating cell membrane construction and material transport [@B19]. Additionally, Annexin A2 has been indicated to be involved in the development of tumors [@B20], [@B21]. It has been demonstrated that Annexin A2 is a potential prognostic factor, and has a stimulatory effect on ovarian cancer [@B17]. Moreover, Annexin A2 is reported to promote cell proliferation and invasion in ovarian cancer via regulating β-catenin/EMT [@B16]. In our study, we showed that TRIM59 was jointed with Annexin A2, which was accordant with our results of the protein mass spectrometry analysis in 293T cells. Moreover, TRIM59 knockdown inhibited Annexin A2 protein expression, whereas TRIM59 over-expression up-regulated Annexin A2 expression. These data suggested that TRIM59 may promote malignant progression of ovarian cancer by inducing Annexin A2 expression.

In summary, increased TRIM59 expression in ovarian cancer tissues was positively associated with clinical parameters such as FIGO stages and metastasis due to the enhanced growth and extensive metastasis. Ovarian cancer patients with high TRIM59 expression were correlated with more unfavorable overall and progression-free survival than the rest patients with low TRIM59 expression. TRIM59 could promote malignant progression of ovarian cancer by inducing Annexin A2 expression. Based on this study, we propose that TRIM59 may serve as a promising prognostic marker and a possible treatment strategy for ovarian cancer.
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![TRIM59 immunohistochemical staining in epithelial ovarian cancer tissues. (A, B) Immunohistochemical detected TRIM59 expression in Grade III epithelial ovarian cancer. (C, D) Immunohistochemical detected TRIM59 expression in Grade I epithelial ovarian cancer. A, B: magnification ×100; C, D: magnification ×200.](ijbsv14p2073g001){#F2}

![TRIM59 expression was up-regulated in human ovarian cancer. (A) RT-PCR examined TRIM59 mRNA expression in normal and neoplastic ovarian epithelial tissue samples. T: ovarian cancer tissues; N: normal epithelial tissues. (B) Immunofluorescence detected the expressions of TRIM59 in frozen section of normal and neoplastic ovarian epithelial issue. Results are displayed as means ± SD from experiments in triplicate. \*, *P* \< 0.05, T compared with N.](ijbsv14p2073g002){#F1}

![The expression of TRIM59 related to overall and progression-free survival in patients with ovarian cancer. (A) Kaplan-Meier survival analysis showed that ovarian cancer patients with high TRIM59 expression were correlated with more unfavorable overall survival than the rest patients with low TRIM59 expression (*P* = 0.0024, log-rank test). (B) Kaplan-Meier survival analysis showed that ovarian cancer patients with high TRIM59 expression were correlated with more unfavorable progression-free survival than the rest patients with low TRIM59 expression (*P* = 7.5×10^-6^, log-rank test).](ijbsv14p2073g003){#F3}

![The construction of TRIM59-shRNA-SKOV3 cell line. (A) Real-time PCR examined the expressions of TRIM59 mRNA in 7 ovarian epithelial cell lines. (B) The transfection efficiency of pUCTP-TRIM59-shRNA and pUCTP-scramble plasmids in SKOV3 cell line. (magnification ×200) (C) Real-time PCR identified the knockdown of TRIM59 in SKOV3 cell line. (D) Western blot identified the knockdown of TRIM59 in SKOV3 cell line. Results are displayed as means ± SD from experiments in triplicate. \*\*\*, *P* \< 0.001.](ijbsv14p2073g004){#F4}

![TRIM59 expression promoted ovarian cancer proliferation, clone formation, and invasion *in vitro*. (A) CCK-8 cell proliferation assay showed that knockdown TRIM59 by shRNA inhibits SKOV3 cell proliferation. (B) Clone formation assay showed that knockdown TRIM59 by shRNA inhibits colony forming ability of SKOV3. (C) 3D matrigel growth assay showed that knockdown TRIM59 by shRNA inhibits SKOV3 cell sphere formation. (D) Transwell cell invasion assay showed that the knockdown TRIM59 by shRNA inhibits the invasion of SKOV3 cell. Results are displayed as means ± SD from experiments in triplicate. \*\*\*, *P* \< 0.001.](ijbsv14p2073g005){#F5}

![TRIM59 expression accelerated ovarian cancer growth *in vivo*. (A, B) *In vivo* xenograft assay showed that the tumor size was significantly decreased after TRIM59 knockdown when compared with the control. (C, D) The orthotopic implantation model revealed that the orthotopic transplantation ovarian tumor growth significantly reduced in the group with TRIM59 knockdown in comparison with the corresponding control group. n=10; \*\*\*, *P* \< 0.001.](ijbsv14p2073g006){#F6}

![TRIM59 induced Annexin A2 expression in ovarian cancer cell lines. (A) To detect the protein expression of TRIM59-FLAG by Western blot and IP. (B) The coomassie staining result of the pooled fractions. (C) The verification of the interaction between exogenous Annexin A2 and TRIM59. (D) TRIM59 knockdown inhibited Annexin A2 protein expression, whereas TRIM59 over-expression up-regulated Annexin A2 expression in ovarian cancer cell lines.](ijbsv14p2073g007){#F7}

###### 

TRIM59 staining and clinicopathological characteristics of 192 ovarian cancer patients.

  Variables               TRIM59 staining                                                      
  ----------------------- ----------------- ----------- ------------ ----------- ----- ------- ---------------------
  Age                                                                                          
  \<52 years                                11          72           6           89    0.846   Mann-Whitney U test
  ≥ 52 years                                9           77           6           92            
  Histological grade                                                                           
  I                                         14(33.33)   26(61.90)    2(4.76)     42    0.000   Kruskal-Wallis test
  II                                        2(2.30)     75(86.21)    10(11.49)   87            
  III                                       1(2.44)     40(97.56)    0(0.00)     41            
  FIGO stage                                                                                   
  I                                         19(14.29)   107(80.45)   7(5.26)     133   0.016   Kruskal-Wallis test
  II                                        0(0.00)     22(95.65)    1(4.35)     23            
  III                                       0(0.00)     14(87.50)    2(12.50)    16            
  IV                                        1(11.11)    6(66.67)     2(22.22)    9             
  T status                                                                                     
  I                                         19(14.39)   106(80.30)   7(5.30)     132   0.073   Kruskal-Wallis test
  II                                        0(0.00)     28(96.55)    1(3.45)     29            
  III                                       1(5.00)     15(75.00)    4(20.00)    20            
  Metastasis                                                                                   
  No                                        19(14.29)   107(80.45)   7(5.26)     133   0.027   Mann-Whitney U test
  Yes                                       1(2.08)     42(87.50)    5(10.42)    48            
  Lymph node metastasis                                                                        
  No                                        19(11.66)   135(82.82)   9(5.52)     163   0.258   Mann-Whitney U test
  Yes                                       1(5.56)     14(77.78)    3(16.67)    18            

Some cases were not available for the information.

###### 

A summary of FLAG-TRIM59 mass spectrometry data

  Peptide Count   \% Cov   Best Disc Score   Best Expect Val   Protein MW   Species   Protein Name
  --------------- -------- ----------------- ----------------- ------------ --------- ----------------------------------------------
  7               25.1     2.61              3.40E-05          38604.4      HUMAN     Annexin A2
  6               25.6     2.83              7.50E-06          35937.1      HUMAN     Annexin A5, UV excision repair protein RAD23
  3               4.2      3.16              5.00E-06          43171.5      HUMAN     homolog B
  2               2.3      2.68              8.10E-06          77039.2      HUMAN     Polyubiquitin-C
  1               2.6      1.42              9.50E-05          55233.4      HUMAN     E3 ubiquitin-protein ligase Mdm2
  12              24.1     3                 1.40E-06          47114.4      HUMAN     Tripartite motif-containing protein 59
  4               19.2     4.98              3.20E-08          27745.3      HUMAN     14-3-3 protein zeta/delta
  2               11.8     3.97              7.80E-08          27764.5      HUMAN     14-3-3 protein theta
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